Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-12-11

Clinical Trial Update: Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53) [Phase 3]

View source ↗

Summary

Phase 3 RACER53 trial results for Viltepso (viltolarsen) in ambulant boys with Duchenne Muscular Dystrophy have been posted, reporting efficacy and safety findi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Viltepso (viltolarsen)

Snippet

Sponsor: NS Pharma, Inc. | Conditions: Duchenne Muscular Dystrophy | Phase 3 | Status: COMPLETED | Results posted: 2024-12-11